This was discovered by scientists of the Gastroesophageal Tumor Unit (CCC-GET) of the Comprehensive Cancer Center (CCC) Vienna of the Medical University of Vienna and Vienna General Hospital in a joint study with the National Institutes of Health, USA and Johns Hopkins University, USA. Esophageal cancer is the eighth most common tumor disease in the Western world, as explained in a recent press release issued by the Medical University of Vienna.
One preliminary stage of adeno carcinoma is the so-called Barrett esophagus, which also exhibits mutations in the mucous membrane. Barrett esophagus leads to esophageal cancer in 0.5% of the cases. In order to prevent a malignant development, physicians recommend the removal of this mucosal change. A biomarker has been potentially identified which indicate which patients should have this changed.
The results of the study suggest that, based on the existence of specific miDNA, it is possible to estimate whether the existing change in the mucous membrane develops into a malignant disease. It would save patients from enduring the removal of the Barrett esophagus and save costs with respect to the follow-up checks of the disease. The 300 patients who participated in the study were procured from Vienna General Hospital.